NCT00849680 - A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016) | Biotech Hunter

Enrollment

317

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

March 31, 2005

Study Completion Date

February 28, 2010

Conditions

HIV-1HIV Infections

Interventions

OTHER

Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine

Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.

BIOLOGICAL

Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)

Monovalent MRKAd5 HIV-1 gag vaccine (1x10\^9 vp/dose)

BIOLOGICAL

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^6 vp/dose)

BIOLOGICAL

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^7 vp/dose)

BIOLOGICAL

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^8 vp/dose)

BIOLOGICAL

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^9 vp/dose)

BIOLOGICAL

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^10 vp/dose)

BIOLOGICAL

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)

Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10\^11 vp/dose)

BIOLOGICAL

Comparator: Placebo to MRKAd5 HIV-1 gag vaccine

Placebo to the MRKAd5 HIV-1 gag vaccine.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY